Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

By P. Muller, Karen H. Vousden. Cancer Cell, 2014

1,443 citations recorded by the source corpus.

Many different types of cancer show a high incidence of TP53 mutations, leading to the expression of mutant p53 proteins. There is growing evidence that these mutant p53s have both lost wild-type p53 tumor suppressor activity and gained functions that help to contribute to malignant progression. Understanding the functions of mutant p53 will help in the development of new therapeutic approaches that may be useful in a broad range of cancer types.

Subfields: Biotechnology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/5f755fb5ab2ac1d4d5f127e60e86a08a4356fc3c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. John N. Weinstein
2. T. Soussi
3. Olivier Lichtarge

In Oncology

1. John N. Weinstein
2. T. Soussi
3. Olivier Lichtarge

Citations in the corpus

• Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. (2015, background): “This clinical gradient of germline TP53 mutations had already been suggested by mouse models of LFS, which had revealed the phenotypic severity of dominant-negative mutations, as compared with null mutations.(29-34) Interestingly, in pedigrees including childhood ACC, we detected, as previously repo”
• Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas (2019, background): “While cell culture studies indicate the mutant p53 protein can behave in a dominant negative fashion to inactivate wildtype p53 protein (Muller and Vousden, 2013)(Giacomelli et al., 2018; Muller and Vousden, 2014; Soussi and Wiman, 2015), the data presented here argue that there is still a strong se”